Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia

Bibliography

• Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20(5):389-409
   PubMed Web of Science ®Google Scholar
• Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Metabotropic glutamate receptors in the control of mood disorders. CNS Neurolog Disord Drug Targets 2007;6:87-100
   PubMedGoogle Scholar
• Linden A-M, Schoepp DD. Metabotropic glutamate receptor targets for neuropsychiatric disorders. Drug Discov Today 2006;3(4):507-17
   Google Scholar
• Schoepp DD. Unveiling the functions of the presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther 2001;299(1):12-20
   PubMed Web of Science ®Google Scholar
• Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-37
   PubMed Web of Science ®Google Scholar
• Schoepp DD, Marek GJ. Preclinical pharmacology of mGluR2/3 receptor agonists: novel agents for schizophrenia? CNS Neurolog Disord Drug Targets 2002;1:215-25
   Google Scholar
• Conn PJ, Lindsley CW, Jones CK. Activation of the metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 2009;30(1):25-31
   PubMed Web of Science ®Google Scholar
• Wright RA, Arnold MB, Wheeler WJ, et al. [3H]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther 2001;298:453-60
   PubMed Web of Science ®Google Scholar
• Monn JA, Valli MJ, Massey SM, et al. Design, synthesis, and pharmacological characteristics of (+)-2-aminobicyclo [3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 1997;40:528-37
   PubMed Web of Science ®Google Scholar
• Monn JA, Valli MJ, Massey SM, et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6,dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem 1999;42:1027-40
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychototmimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214
   PubMed Web of Science ®Google Scholar
• Lahti AC, Keffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psyschosis in schizophrenia. Neuropsychopharmacology 1995;13:9-19
   PubMed Web of Science ®Google Scholar
• Cartmell J, Monn JA, Schoepp DD. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behavior in rats. J Pharmacol Exp Ther 1999;291(1):161-70
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Adams BW. Reversal of phencyclidine effects by group II metabotropic glutamate receptor agonists in rats. Science 1998;281:1349-52
   PubMed Web of Science ®Google Scholar
• Krystal JH, Abi-Saab W, Perry E, et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with a group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2005;179:303-9
   PubMed Web of Science ®Google Scholar
• Monn JA, Massey SM, Valli MJ, et al. Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (–)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identification of potent, selective, and orally bioavailable agonists for mGlu2/3 receptors. J Med Chem 2007;50(2):233-40
   Google Scholar
• Woolley ML, Pemberton DJ, Bate S, et al. The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity. Psychopharmacology 2008;196:431-40
   PubMed Web of Science ®Google Scholar
• Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of the metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (–)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2008;326(1):209-17
   PubMed Web of Science ®Google Scholar
• Patil ST, Zhang L, Martenyi F, et al. Activation of mGluR2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13:1102-7
   PubMed Web of Science ®Google Scholar
• Johnson MP, Baez M, Jagdmann GE, et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J Med Chem 2003;46:3189-92
   PubMed Web of Science ®Google Scholar
• Schaffhauser H, Rowe BA, Morales S, et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol 2003;64(4):798-810
   Google Scholar
• Rowe BA, Schaffhauser H, Morales S, et al. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site. J Pharmacol Exp Ther 2008;326(1):240-51
   PubMed Web of Science ®Google Scholar
• Johnson MP, Barda B, Britton TC, et al. Metabotropic glutamate receptor 2 potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology 2005;179:271-83
   PubMed Web of Science ®Google Scholar
• Bonnefous C, Vernier J-M, Hutchinson JH, et al. Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett 2005;15:4354-8
   PubMed Web of Science ®Google Scholar
• Galici R, Echemendia NG, Rodriquez AL, Conn PJ. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGluR2/3 receptor agonist in mouse models predictive of antipsychotic activity. J Pharmacol Exp Ther 2005;315(3):1181-7
   PubMed Web of Science ®Google Scholar
• Galici R, Jones CK, Hemstapat K, et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther 2006;318(1):173-85
   PubMed Web of Science ®Google Scholar
• Rudd MT, McCauley JA. Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2). Curr Top Med Chem 2005;5:869-84
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Acetophenone potentiators of metabotropic glutamate receptors. WO2004018386; 2004
   Google Scholar
• Pinkerton AB, Vernier J-M, Schaffhauser H, et al. Phenyl-tetrazoyl acetophenones: discovery of positive allosteric potentiators for the metabotropic glutamate 2 receptor. J Med Chem 2004;47:4595-9
   PubMed Web of Science ®Google Scholar
• Pinkerton AB, Cube RV, Hutchinson JH, et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGluR2). Part 1: identification and synthesis of phenyl-tetrazolyl acetophenones. Bioorg Med Chem Lett 2004;14:5329-32
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company. Potentiators of glutamate receptors. WO2006057860; 2006
   Google Scholar
• Eli Lilly and Company. Potentiators of glutamate receptors. WO2006057869; 2006
   Google Scholar
• Eli Lilly and Company. Potentiators of glutamate receptors. WO2006057870; 2006
   Google Scholar
• Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors. WO2006014918; 2006
   Google Scholar
• Pinkerton AB, Cube RV, Hutchinson JH, et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGluR2). Part 2: 4-thiopyridyl acetophenones as non-tetrazole containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 2004;14:5867-72
   PubMed Web of Science ®Google Scholar
• Cube RV, Vernier J-M, Hutchinson JH, et al. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)-phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med Chem Lett 2005;15:2389-93
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors. WO2006015158; 2006
   Google Scholar
• Pinkerton AB, Cube RV, Hutchinson JH, et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGluR2). Part 3: identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med Chem Lett 2005;15:1565-71
   Google Scholar
• Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors. WO2006047237; 2006
   Google Scholar
• Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors. WO2006091496; 2006
   Google Scholar
• Govek SP, Bonnefous C, Hutchinson JH, et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model of schizophrenia. Bioorg Med Chem Lett 2005;15:4068-72
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutica N.V. and Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors. WO2006030032; 2006
   Google Scholar
• Janssen Pharmaceutica N.V. and Addex Pharmaceuticals S.A. 1,4-Disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors. WO2007104783; 2007
   Google Scholar
• Janssen Pharmaceutica N.V. and Addex Pharmaceuticals S.A. 3-Cyano-4-(4-phenyl-piperidin-1yl)-pyridin-2-one derivatives. WO2008107479; 2008
   Google Scholar
• Janssen Pharmaceutica N.V. and Addex Pharmaceuticals S.A. 1,4-Disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mGluR2-receptors. WO2008107480; 2008
   Google Scholar
• Janssen Pharmaceutica N.V. and Addex Pharmaceuticals S.A. 3-Cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one pyridone derivatives. WO2008107481; 2008
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharmaceuticals S.A. 1′,3′-Disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones. WO2009033704;2009
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharmaceuticals S.A. 1,3-Disubstituted 4-(aryl-x-phenyl)-1H-pyridin-2-ones. WO2009033702; 2009
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Addex Pharmaceuticals S.A. 1,3-Disubstituted-4-phenyl-1H-pyridin-2-ones. WO2009033703; 2009
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Isoindolone compounds and their use as metabotropic glutamate receptor potentiators. WO2006020879; 2006
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Metabotropic glutamate-receptor-potentiating isoindolones. WO2007021308; 2007
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Substituted isoindolones and their use as metabotropic glutamate receptor potentiators. WO2007021309; 2007
   Google Scholar
• AstraZeneca AB. Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators. WO2008150232; 2008
   Google Scholar
• AstraZeneca AB. Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators. WO2008150233; 2008
   Google Scholar
• AstraZeneca AB. Aza-isoindolones and their use as metabotropic glutamate receptor potentiators. WO2008100715; 2008
   Google Scholar
• AstraZeneca AB. Hydrazides and their use as metabotropic glutamate receptor potentiators. WO2008130853; 2008
   Google Scholar
• Abbott GMBH & Co. KG. Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor). WO2008145616; 2008
   Google Scholar
• González-Maeso J, Ang RL, Yuen T, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008;452:93-9
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators. WO2007078523; 2007
   Google Scholar
• AstraZeneca AB. Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators. WO2008032191; 2008
   Google Scholar
• Pfizer, Inc. N-Benzyl oxazolidinones and related heterocyclic compounds as potentiators of glutamate receptors. WO2009004430; 2009
   Google Scholar
• Duplantier AJ, Efremov I, Candler J, et al. 3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: hit-to-lead and lead optimization. Bioorg Med Chem Lett 2009;19:2524-9
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators. WO2007115077; 2007
   Google Scholar
• Pfizer Products, Inc. Benzimidazolyl compounds as potentiators of mGluR2 subtype of glutamate receptor. WO2008012623; 2008
   Google Scholar
• Pfizer Products, Inc. Benzimidazolyl compounds. WO2007135527; 2007
   Google Scholar
• Pfizer Products, Inc. Azabenzimidazolyl compounds. WO2008012622; 2008
   Google Scholar
• Pfizer Products, Inc. Benzimidazolyl compounds. WO2007135529; 2007
   Google Scholar
• Zhang L, Rogers BN, Duplantier AJ, et al. 3-(Imidazoyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: A novel series of mGluR2 positive allosteric modulators. Bioorg Med Chem Lett 2008;18:5493-6
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors. WO2006049968; 2006
   Google Scholar
• Hu E, Chua PC, Tehrani L, et al. Pyrimidine methyl anilines: selective potentiators for the metabotropic glutamate 2 receptor. Bioorg Med Chem Lett 2004;14:5071-4
   Google Scholar
• Barda DA, Wang Z-Q, Britton TC, et al. SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Bioorg Med Chem Lett 2004;14:3099-102
   Google Scholar
• Janssen Pharmaceutica N.V. and Addex Pharmaceuticals S.A. Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mGluR2-receptors. WO2006030031; 2006
   Google Scholar
• AstraZeneca AB and NPS Pharmaceuticals, Inc. Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders. WO2006071730; 2006
   Google Scholar
• Sanofi-Aventis. Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof. WO2008112483; 2008
   Google Scholar
• Dunayevich E, Erickson J, Levine L, et al. Efficacy and tolerability of an mGluR2/3 agonist in the treatment of generalized anxiety order. Neuropsychopharmacology 2008;33:1603-10
   PubMed Web of Science ®Google Scholar
• Cartnell J, Monn JA, Schoepp DD. Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activitities by oral administration of the mGluR2/3 receptor agonist, LY379268. Naunyn Schmiedebergs Arch Pharmacol 2000;361:39-46
   Google Scholar